Amazon.com, Inc. (NASDAQ:AMZN) shares were downgraded by Janney Capital Markets after the online retailer late Thursday reported weaker-than-expected Q3 results and forecast Q4 sales below the Street view. Janney cut its investment rating on AMZN to neutral from buy while slashing its target price on the stock to $315 from $400. Amazon.com, Inc. (NASDAQ:AMZN) shares were down 9.2% at $284.25 in recent trading, putting the stock on track to trade near or below its 52-week low of $284.38 if the drop is sustained in the regular session."The key change is slowing growth," Janney told clients as it announced the downgrade in a note. It added: "While there are positive drivers to the AMZN growth story--including strong share gains in NA EGM, strong renewal rates on Prime, and increasing usage of video content, there are signs of increasing weakness in International (some of which may be recent weakness in UK online retail) and slower growth in N.A. Media (tough comps on video game consoles)." Analysts at Cowen also downgraded AMZN Thursday, cutting it to market perform from outperform.ImmunoGen, Inc. (NASDAQ:IMGN) a biotechnology company developing anticancer therapeutics, announced a fiscal Q1 loss that was wider than expected by analysts and revenues that fell short of expectations. ImmunoGen, Inc. (NASDAQ:IMGN) reported a Q1 loss of $0.26, wider than the loss of $0.13 reported in Q1 2014 and wider than the loss of $0.15 expected by analysts. Total revenues of $13.2 million were down from $17.2 million in Q1 2014 and missed analyst projections of $23.5 million for the quarter. The company reaffirmed guidance for the full fiscal year, expecting revenues between $100 million and $105 million and a net loss between $60 million and $65 million. Shares of IMGN are at $9.22 within a 52-week range of $7.70 - $18.19.First Citizens Banc Corp (NASDAQ:FCZA) posted a gain in Q3 earnings and revenue as interest income rose, though the results missed an analyst's forecast. Net income attributable to common shares was $1.9 million, or $0.21 per share, an increase of 48.8% compared with $1.3 million, or $0.17 per share, in the prior year period. That misses the estimate of one analyst by one cent. Net interest income rose to $10.68 million from $9.91 million. Non-interest income was $3.01 million, little changed from $3.07 million a year ago. Combined that misses the estimate for revenue in the quarter of $14 million. The shares closed at $10.32 on Thursday with a 52-week spread of $6.16 - $10.50.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
